Studies have also shown that mTOR and HDAC inhibitors act by converging on the TXNIP antioxidant pathway to co-affect chromatin and transcription, resulting in the death of aggressive neurological malignancies and tumor shrinkage. Here, TXNIP is linked to neoplasm.